Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Cellectis cash
Cash and short-term investments held at the end of each period.
Cellectis's cash was $35.59M at Jun 30, 2026. For fiscal 2025 it was $61.53M, down 57.0% from the year before. Over ten years it grew -15.8% a year on average. The highest annual figure on record is $451.50M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.53M | -57.0% |
| FY2024 | Dec 31, 2024 | $143.25M | +4.8% |
| FY2023 | Dec 31, 2023 | $136.71M | +46.7% |
| FY2022 | Dec 31, 2022 | $93.22M | -49.8% |
| FY2021 | Dec 31, 2021 | $185.64M | -23.0% |
| FY2020 | Dec 31, 2020 | $241.15M | -29.2% |
| FY2019 | Dec 31, 2019 | $340.52M | -24.6% |
| FY2018 | Dec 31, 2018 | $451.50M | +76.1% |
| FY2017 | Dec 31, 2017 | $256.38M | +0.7% |
| FY2016 | Dec 31, 2016 | $254.57M | -25.6% |
| FY2015 | Dec 31, 2015 | $342.11M | +150.8% |
| FY2014 | Dec 31, 2014 | $136.40M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $35.59M | -76.1% |
| Q4 FY2025 | Dec 31, 2025 | $61.53M | -55.0% |
| Q2 FY2025 | Jun 30, 2025 | $59.81M | -29.1% |
| Q4 FY2024 | Dec 31, 2024 | $143.25M | +53.7% |
| Q2 FY2024 | Jun 30, 2024 | $149.04M | +15.1% |
| Q4 FY2023 | Dec 31, 2023 | $136.71M | -26.4% |
| Q2 FY2023 | Jun 30, 2023 | $84.39M | -66.0% |
| Q4 FY2022 | Dec 31, 2022 | $93.22M | -61.3% |
| Q2 FY2022 | Jun 30, 2022 | $129.44M | -50.4% |
| Q4 FY2021 | Dec 31, 2021 | $185.64M | -45.5% |
| Q2 FY2021 | Jun 30, 2021 | $248.23M | -37.5% |
| Q4 FY2020 | Dec 31, 2020 | $241.15M | -46.6% |
| Q2 FY2020 | Jun 30, 2020 | $260.71M | +1.7% |
| Q4 FY2019 | Dec 31, 2019 | $340.52M | +33.8% |
| Q2 FY2019 | Jun 30, 2019 | $396.97M | +16.0% |
| Q4 FY2018 | Dec 31, 2018 | $451.50M | +231.0% |
| Q4 FY2017 | Dec 31, 2017 | $256.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $254.57M | – |
| Q4 FY2015 | Dec 31, 2015 | $342.11M | – |
| Q4 FY2014 | Dec 31, 2014 | $136.40M | – |
See a number that looks wrong?